Phage Therapy for Hospital-Acquired Respiratory Bacterial Infections: A Review

Area of Science:

• Microbiology
• Infectious Diseases
• Therapeutics

Background:

• Antibiotic resistance in respiratory pathogens is a growing global health concern.
• Hospital-acquired pulmonary infections pose significant treatment challenges.
• Bacteriophage therapy is gaining traction as an alternative to antibiotics.

Purpose of the Study:

• To review recent advancements in bacteriophage therapy for drug-resistant nosocomial pulmonary infections.
• To consolidate findings from animal research, clinical cases, and trials.
• To highlight phage therapy's potential against key pathogens like Pseudomonas aeruginosa and Klebsiella pneumoniae.

Main Methods:

• Literature review of studies on bacteriophage therapy for respiratory infections.
• Inclusion of in vivo experiments, compassionate use cases, and clinical trials.
• Focus on clinically relevant, drug-resistant bacterial targets.

Main Results:

• Phage therapy has shown potential against Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii.
• Investigated applications include in vivo models and compassionate use for Mycobacterium abscessus.
• Recent research indicates growing interest and application in Western countries.

Conclusions:

• Bacteriophage therapy is a viable strategy for combating antibiotic-resistant respiratory pathogens.
• Further research and clinical trials are essential to establish phage therapy's efficacy and safety.
• Phage therapy represents a crucial adjunctive or alternative treatment for nosocomial lung infections.